Keywords: BB; bevacizumab-bevacizumab; BP; bevacizumab followed by panitumumab; CA9; carbonic anhydrase 9; CRC; colorectal cancer; DEGs; differentially expressed genes; EGFR; epidermal growth factor receptor; EPHA2; ephrin type-A receptor 2; FASN; fatty acid syntha
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Anti-EGFR therapy; Convenience of outpatient; Fully humanized monoclonal antibody; Infusion-related reaction; mCRC;
Keywords: Low dose; Metronomic chemotherapy; Metastatic colorectal cancer; CRC; colorectal cancer; mCRC; metastatic colorectal cancer; MTD; maximal tolerated dose; PFS; progression-free survival; OS; overall survival; TSP-1; thrombospondin-1;
Keywords: ANOVA; analysis of variance; DEE; drug-eluting embolic; HCC; hepatocellular carcinoma; ICC; intrahepatic cholangiocarcinoma; mCRC; metastatic colorectal carcinoma; SHAPD; systemic-hepatic artery pressure difference; SIS; Surefire Infusion System; TARE; tr
Keywords: ADCC; antibody-dependent cell-mediated cytotoxicity; AKT; protein kinase B; ATP; adenosine triphosphate; cfDNA; circulating free DNA; CISH; chromogenic in-situ hybridization; CTC; circulating tumor cells; EGFR; epithelial growth factor receptor; EMT; epit
Keywords: Colorectal; Targeted therapy; Metastatic colorectal cancer; Molecular markers; Biologic therapy; mCRC; metastatic colorectal cancer; CRC; colorectal cancer; OS; overall survival; DFI; disease free interval; MSI; microsatellite instability; CTC; circulatin
Keywords: Transarterial therapy; follow-up; hepatic malignancy; survey; IO; Interventional Oncology; IR; Interventional Radiology; LRT; locoregional therapy; SIR; Society of Interventional Radiology; CT; computed tomography; TACE; transarterial chemoembolization; c
Keywords: BSA; body surface area; CEA; carcinoembryonic antigen; DWL; whole-liver absorbed dose; mCRC; metastatic colorectal carcinoma; RECIST; Response Evaluation Criteria in Solid Tumors; REILD; radioembolization-induced liver disease; SPECT; single photon emissi
Keywords: aFGF; acidic fibroblast growth factor; Ang-2; angiopoietin-2; bFGF; basic fibroblast growth factor; Conc; concentration; FGFR; fibroblast growth factor receptor; G-CSF; granulocyte colony-stimulating factor; GM-CSF; granulocyte-macrophage colony-stimulati
KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease
Keywords: mCRC; KRAS mutation; PI3KCA mutation; FIr-B/FOx; Anti-VEGF; Anti-EGFR;
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial
Keywords: Elderly; Aflibercept; mCRC; Second-line; VEGF-Trap; VELOUR;
Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales
Keywords: Cost-utility; Economic model; mCRC; NICE; TAS-102;
A Low-Toxicity DNA-Alkylating N-Mustard-Quinoline Conjugate with Preferential Sequence Specificity Exerts Potent Antitumor Activity Against Colorectal Cancer
Keywords: AST; aspartate transaminase; ALT; alanine transaminase; BUN; blood urea nitrogen; CBC; complete blood count; CRC; colorectal cancer; DMSO; dimethyl sulfoxide; D5W; 5% dextrose isotonic solution; FHC; fetal human colon epithelial cells; H&E; hematoxylin an
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study
Keywords: Activin receptor like-protein 1; Angiogenesis; Biomarker; mCRC; Prognostic;
Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial
Keywords: AJCC; American Joint Committee on Cancer; AP; alkaline phosphatase; BRAF; v-Raf murine sarcoma viral oncogene homolog B; CI; confidence interval; CRC; (colorectal cancer); CT; computed tomography; ECOG; Eastern Cooperative Oncology Group scale of performa
Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies
Keywords: mCRC; RAS mutant; RAS WT; Treatment lines; Tumor location;
Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients
Keywords: Biomarker; Digital droplet PCR; Liquid biopsies; mCRC; NPY;
Emerging paradigms in the treatment of liver metastases in colorectal cancer
Keywords: CRC; colorectal cancer; mCRC; metastatic colorectal cancer; CLM; colorectal liver metastases; SR; surgical resection; PVE; portal vein embolism; RFA; radiofrequency ablation; APC; adenomatous polyposis coli; LOH; loss of heterozygosity; EGFR; epidermal gr
Bispecific antibodies for cancer therapy: A review
Keywords: ADCC; antibody-dependent cell-mediated cytotoxicity; AE; adverse events; ALL; acute lymphoblastic leukemia; ALP; alkaline phosphatase; ALT; alanine aminotransferase; AST; aspartate aminotransferase; B-ALL; B-cell acute lymphoblastic leukemia; BiTES; Bi-sp
DNA mismatch repair in cancer
Keywords: 5-FU; 5-fluorouracil; bMMRD; Biallelic mismatch repair deficiency; CD28; cluster of differentiation 28; CIN; Chromosomal instable; CR; complete response; CRC; colorectal cancer; CTL; cytotoxic T-lymphocytes; CTLA-4; cytotoxic T lymphocyte antigen-4; DFS;
Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency
Keywords: CRC; colorectal cancer; mCRC; metastatic CRC; CTLA4; cytotoxic T-lymphocyte-associated antigen 4; EGFR; epithelial growth factor receptor; HR; hazard ratio; MAP; mitogen-activated protein; mAb; monoclonal antibody; MEK; mitogen-activated protein/extracell
Cytokine balance and behavioral intervention; findings from the Peer Approaches to Lupus Self-Management (PALS) project
Keywords: SLE; Systemic Lupus Erythematosus; PALS; Peer Approaches to Lupus Self-Management; PROs; patient reported outcomes; MCRC; Multidisciplinary Clinical Research Center; MUSC; Medical University of South Carolina; CDMP; Chronic Disease Self-Management Program
Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR
Keywords: NSCLC; non-small cell lung cancer; TKI; tyrosine kinase inhibitor; PFS; progression-free survival; SARMS; Scorpion Amplification Refractory Mutation System; dPCR; digital polymerase chain reaction; ddPCR; picodroplet dPCR; mCRC; metastatic colorectal ca
STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics
Keywords: STAT3; EGFR; Therapeutics; Cancer; EGF; Epidermal Growth Factor; EGFR; Epidermal Growth Factor Receptor; TGFα; Transforming Growth Factor-alpha; TGFβ; Transforming Growth Factor-beta; mAb; monoclonal antibody; TKI's; Tyrosine kinase inhibitors; mCRC; me
Original ResearchHealth-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
Keywords: HRQoL; mCRC; Chemotherapy; RAS and BRAF mutation status; Inflammation;
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Keywords: Depth of response; Dosing schedule; Early tumor shrinkage; Erbitux; mCRC;
Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy
Keywords: CRYSTAL; FOLFIRI; Global health status (GHS); mCRC; QoL;
ReviewRAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer
Keywords: Cetuximab; KRAS; mCRC; NRAS; Panitumumab;
FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study
Keywords: Cetuximab; CRYSTAL; LLD; R0 resection; RAS; mCRC;
Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials
Keywords: Panitumumab; mCRC; RAS prevalence; KRAS; NRAS; BRAF;
Original articleClinical endoscopyMetachronous colorectal cancers result from missed lesions and non-compliance with surveillance
Keywords: CRC; colorectal cancer; mCRC; metachronous CRC; PALGA; national pathology database; TNM; tumor, node, metastasis;
Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers
Keywords: FISH; Topoisomerase 1; Topoisomerase 2A; MMR; Chromosomal instability; Gene copy number; TOP1; gene symbol for the gene encoding topoisomerase 1; TOP2A; gene symbol for the gene encoding topoisomerase 2 alpha; CEN17; symbol for the chromosomal region enco
Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology
Keywords: PDX; patient derived xenograft; CDX; cell line derived xenograft; CRD; clinically relevant dose; TIC; tumor initiating cell; NSG; NOD scid gamma; NSCLC; non-small cell lung cancer; CSC; cancer stem cell; SOC; standard of care; MTD; maximum tolerated dose;
Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis
Keywords: Colorectal cancer; Prognosis; FISH; Topoisomerase 1; Gene copy number; Biomarker; CEN-20; centromere 20; CC; colon cancer; CI; confidence interval; CRC; colorectal cancer; DFS; disease free survival; 5FU; 5-fluorouracil; FFPE; formalin-fixed paraffin-embe
microRNAs in colon cancer: A roadmap for discovery
Keywords: miRNA; microRNAs; CRC; Colorectal cancer; mCRC; Metastatic colorectal cancer; ncRNA; Non-coding RNA; ISH; In situ hybridization; FFPE; Formalin-fixed paraffin-embedded; NGS; Next Generation Sequencing; MSI-H; Microsatellite instability (high); MSI-L; Micr
Development of a Research Agenda for the Management of Metastatic Colorectal Cancer: Proceedings from a Multidisciplinary Research Consensus Panel
Keywords: AHRQ; Agency for Healthcare Research and Quality; CLM; colorectal liver metastases; CRC; colorectal cancer; DEBIRI; drug-eluting beads loaded with irinotecan; FLR; future liver remnant; FOLFIRI; folinic acid/5-fluorouracil/irinotecan [systemic chemotherap
The role of cetuximab in converting initially unresectable colorectal cancer liver metastases for resection
Keywords: Conversion therapy; Resection; Cetuximab; MDT; mCRC;